Rationally designed PKA inhibitors for positron emission tomography: Synthesis and cerebral biodistribution of N-(2-(4-bromocinnamylamino)ethyl)-N-[11C]methyl-isoquinoline-5-sulfonamide
-
Add time:07/18/2019 Source:sciencedirect.com
Protein kinase A (PKA) is an important signal transduction target for drug development because it influences critical cellular processes implicated in neuropsychiatric illnesses such as major depressive disorder. The goal of the present study was to develop the first imaging agent for measuring the levels of PKA with positron emission tomography (PET). By rational derivatization of 5-isoquinoline sulfonamides, it was found that the introduction of a methyl group to the sulphonamidic nitrogen on the known PKA inhibitors N-(2-aminoethyl)isoquinoline-5-sulfonamide (H-9, 1) and N-(2-(4-bromocinnamylamino)ethyl)isoquinoline-5-sulfonamide (H-89, 2), (yielding N-(2-aminoethyl)-N-methyl-isoquinoline-5-sulfonamide (4) and N-(2-(4-bromocinnamylamino)ethyl)-N-methyl-isoquinoline-5-sulfonamide (5), respectively) does not appreciably reduce in vitro potency toward PKA. We have facilitated the synthesis of 4 by reacting isoquinoline-5-sulfonyl chloride with N-methylethylenediamine (20% yield). Several techniques were used to thoroughly characterize 4 including multi (1H, 13C and 15N) NMR spectroscopy and X-ray crystallography. Compound 4 and 1-(4-bromophenyl)-1-propen-3-yl bromide were reacted to produce 5 in 16% yield. Compound 2 was reacted with [11C]CH3I to prepare N-(2-(4-bromocinnamylamino) ethyl)-N-[11C]methyl-isoquinoline-5-sulfonamide ([11C]5), with a decay-corrected radiochemical yield of 32%, based on [11C]CO2. [11C]5 was produced with >98% radiochemical purity and 1130 mCi/μmol specific activity after 40 min (end of synthesis). Conscious rats were administered [11C] 5 and sacrificed at 5, 15, 30 and 60 min after injection. Radioactivity from all excised brain regions was <0.2%ID/g at all time points. The modest brain penetration of [11C]5 may limit its use for studying PKA in the central nervous system.
We also recommend Trading Suppliers and Manufacturers of N-(2-[(4-BROMOPHENYL)SULFONYL]ETHYL)-2,4-DICHLOROBENZENECARBOXAMIDE (cas 338955-75-2). Pls Click Website Link as below: cas 338955-75-2 suppliers
Prev:BF3-promoted reactions between aryl aldehydes and 3-diazoindolin-2-imines: Access to 2-amino-3-arylindoles
Next:Regioselective 1,2-additions of alcohols to allenamides mediated by N-Iodosuccinimide: Synthesis of N,O-aminals) - 【Back】【Close 】【Print】【Add to favorite 】
- Related Information
- 4-(3-Alkyl-2-oxoimidazolidin-1-yl)-N-phenylbenzenesulfonamides as new antimitotic prodrugs activated by cytochrome P450 1A1 in breast cancer cells07/21/2019
- Regioselective 1,2-additions of alcohols to allenamides mediated by N-Iodosuccinimide: Synthesis of N,O-aminals07/19/2019
- BF3-promoted reactions between aryl aldehydes and 3-diazoindolin-2-imines: Access to 2-amino-3-arylindoles07/17/2019
- Flexible, N-sulfonyl-substituted aliphatic amine ligands in palladium-catalyzed Suzuki–Miyaura CC coupling: Influence of substituents bulkiness and co-ligand size07/16/2019
- β-amino alcohols and their respective 2-phenyl-N-alkyl aziridines as potential DNA minor groove binders07/15/2019
- Photoredox-catalyzed sulfenylation/cyclization of N-aryl-N-tosylpropargylamine with disulfide: A concise route to 3-phenylthioquinoline07/14/2019
- 2-(Phenylsulfonyl)quinoline N-hydroxyacrylamides as potent anticancer agents inhibiting histone deacetylase07/13/2019
- 2-Methylquinoline promoted oxidative ring-opening of N-sulfonyl aziridines with DMSO: facile synthesis of α-amino aryl ketones07/12/2019
- Design, synthesis and preliminary bioactivity studies of indomethacin derivatives as Bcl-2/Mcl-1 dual inhibitors07/11/2019


